Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome
DEVON, PA — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced that it has successfully achieved its patient screening target …
Read More